Evidence map›Paper›PMID 39817085›Full record

ArticleJACC. Advances2024

Valvular Heart Disease-Related Mortality Between Middle- and High-Income Countries During 2000 to 2019.

Makoto Hibino, Hiroki A Ueyama, Michael E Halkos, Kendra J Grubb, Raj Verma, Azeem Majeed, Christoph A Nienaber, Bobby Yanagawa, Deepak L Bhatt, Subodh Verma

Abstract read
In one paragraph

Article in JACC. Advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Biofidelic Simulations of the Ross Procedure: Arterial Growth and Remodeling in an Anatomical Context.International journal for numerical methods in biomedical engineering · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Makoto HibinoDepartment of Thoracic and Cardiovascular Surgery, Heart, Vascular, and Thoracic Institute, Cleveland Clinic Cleveland, Ohio, USA.
Hiroki A UeyamaDivision of Cardiology, Emory University School of Medicine, Atlanta, Georgia, USA.
Michael E HalkosDivision of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia, USA.
Kendra J GrubbDivision of Cardiothoracic Surgery, Emory University School of Medicine, Atlanta, Georgia, USA.
Raj VermaRoyal College of Surgeon in Ireland, Dublin, Ireland.
Azeem MajeedDepartment of Primary Care and Public Health, School of Public Health, Imperial College London, London, United Kingdom.
Christoph A NienaberCardiology and Aortic Centre, Royal Brompton and Harefield Hospitals, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom.
Bobby YanagawaDivision of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, Toronto, Ontario, Canada.
Deepak L BhattMount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Subodh VermaDivision of Cardiac Surgery, St. Michael's Hospital of Unity Health Toronto, Toronto, Ontario, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Valvular heart disease (VHD) management has evolved rapidly in recent decades, but disparities in health care access persist among countries with varying socioeconomic backgrounds. Objectives: The purpose of this study was to investigate global mortality trends from VHD and assess the difference between middle- and high-income countries. Methods: We obtained mortality data from the World Health Organization Mortality Database for VHD and its subgroups (rheumatic valvular disease [RVD], infective endocarditis [IE], aortic stenosis [AS], and mitral regurgitation [MR]) from 2000 to 2019. Age-specific and age-standardized mortality rates per 100,000 persons in middle- and high-income countries were calculated, and trends were analyzed using joinpoint regression. Results: A total of 93 countries (42 middle-income and 51 high-income) were included in the analysis. Both middle- and high-income countries showed an increasing trend in crude VHD mortality rate. In middle-income countries, the age-standardized VHD-related mortality rate was constant (0.0%/year), with decreasing RVD (-2.7%/year) and increasing IE, AS, and MR (0.8%/year, 2.0%/year, and 2.2%/year, respectively). In high-income countries, the age-standardized VHD-related mortality rate was decreasing (-0.6%/year). However, there was a rapid increase in mortality rate from IE in age ≤39 years after 2009 (7.0%/year). Moreover, there was a decreasing mortality rate from AS after 2015 but an increasing rate from MR after 2013, particularly in age ≥80 years. Conclusions: Our study identified a rising burden of VHD-related mortality worldwide. The distribution and trends of VHD mortality differed between middle- and high-income countries. Further investigation is needed to understand the underlying etiology of these varying mortality trends in VHD and its subgroups.

Indexed as

global mortality trendsnational income levelsvalvular heart disease

Identifiers

PMID39817085
PMCPMC11733992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.